We are a genetics medicine company based in Philadelphia, PA, a city with a rich history of scientific discovery and medical advancement. As a leading developer of cutting-edge therapeutics for disorders of the central nervous system (CNS), we are proud to be a part of this dynamic research community. We are also excited about our new laboratory at the Princeton West Innovation Campus in Hopewell, New Jersey, which will help us evolve the standard for biotech innovation and development. At Passage Bio, we have a bold vision to fulfill the promise of gene therapy and a differentiated approach to gene therapy development through our collaboration with University of Pennsylvania's Gene Therapy Program and Orphan Disease Center. Our deep pipeline of optimized gene therapies for CNS disorders includes lead programs focused on the following devastating diseases: GM1 gangliosidosis Krabbe disease Frontotemporal dementia